secwatch.observer — SEC 8-K summary
======================================

Issuer:     Elicio Therapeutics, Inc. (ELTX)
CIK:        0001601485
Form:       8-K
Filed at:   2026-08-13T20:06:49+00:00
Accession:  0001601485-26-000055
Event type: earnings
Sentiment:  negative
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Elicio Q2 net loss $8.2M; Phase 2 AMPLIFY-7P trial misses primary endpoint
--------------------------------------------------------------------------

- Phase 2 AMPLIFY-7P trial of ELI-002 7P in adjuvant mKRAS pancreatic cancer did not meet primary endpoint; evaluating R0 resected subgroup for Phase 3 strategy.
- Q2 2026 net loss $8.2M ($0.43/share) vs $10.6M ($0.66/share) in Q2 2025; R&D expense $6.8M, G&A $3.6M.
- Cash $23.5M at June 30, 2026; July 2026 $15.0M registered direct offering; runway into Q1 2027.
- Plans Phase 1 combo study of ELI-002 7P + RAS inhibitor ± anti-PD-1 in metastatic pancreatic cancer, Q4 2026; multiple complete responses observed.
- MSK-led Phase 1 neoadjuvant trial of ELI-002 7P + chemo + checkpoint inhibition activated.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1601485/000160148526000055/0001601485-26-000055-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1601485/000160148526000055/eltx-20260813.htm
  HTML page:      https://secwatch.observer/filing/0001601485-26-000055

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer